

PERSONAL DETAILS:

Full Name :	Andrea Patriarca
Specialty:	Hematology
Home Address:	Strada Statale 17, 32, 86170, Isernia
E-mail Address:	andreapatriarca80@gmail.com
Telephone (home):	+390865411506
Telephone (mobile):	+393319949337/+447497775374
Nationality:	Italian
Gender:	Male
Date of Birth:	24 December 1980
Marital Status:	Married

KNOWLEDGE OF LANGUAGES:

Language:	Skill
Italian	Native
English	B2
Danish	B1

QUALIFICATIONS/EDUCATION:

From (year):	To (year):	Name and location (city) of University	Subject or specialty	Level of course (diploma, degree, certificate, etc)
1999	2006	Medicine and Surgery, Univeristà "G. d'Annunzio", Chieti, advisor Giovanni Davi	Medicine and Surgery	Degree
2007	2011	Hematology speciality course, Univeristà "G. d'Annunzio", Chieti, advisor Giovanni Davi	General Hematology	Diploma

MEDICAL AND ACADEMIC DEGREES:

Degree	Subject or Specialty	Year
Medicine and Surgery	General Medicine	2006
Hematologist diploma	General clinical and laboratory hematology	2011

CURRENT EMPLOYMENT:

From (year):	To (year)	Employer	Location (City)	Position
2017	today	Ospedale Maggiore della Carità	Novara (NO)	Locum Consultant (Dirigente Medico)

PREVIOUS EMPLOYMENT:

From: (year)	To: (year)	Employer	Location (City)	Position
2007	2011	Università degli Studi "G. d'Annunzio"	Chieti	Young physician
2011	2012	Haematological department, "S. Spirito" Hospital	Pescara	Freelance specialist on behalf of AIL
2012	2013	ASL Piemonte 11	Vercelli	Consultant in hematology
2013	2014	Sygehuset Lillebælt	Vejle, Denmark	Consultant
2014	2014	Fondazione "Papa Giovanni Paolo II"	Campobasso (IT)	Assistant
2015	2015	"Infermi" Hospital	Biella (IT)	Locum Consultant
2015	Feb 2016	"Northern Lincolnshire NHS Trust"	Grimsby (UK)	Locum Consultant
Feb 2016	March 2017	IRCCS (Cancer Scientific and Research Center) CROB	Rionero in Vulture (IT)	Locum Consultant

TEACHING RESPONSIBILITIES:

2017-today: Lecturer ("professore a contratto") of "Haematology" at Nursing Degree of the School of Medicine of Università del Piemonte Orientale. Moreover, as Lecturer I supervised the thesis of the student in the master degree in Medical Biotechnology (international degree).

2020-today: Lecturer ("professore a contratto") of "Hemopoietic stem cell biology and transplantation" at Master Degree in Medical Biotechnology of the School of Medicine of Università del Piemonte Orientale (international degree).

RESEARCH AND PUBLICATIONS

RESEARCH

- 2008-2010: Subinvestigator protocol A8851009 "A prospective, randomized trial comparing the efficacy of anidulafungin and voriconazole in combination to that of voriconazole alone when used for primary therapy of proven or probable invasive aspergillosis".
- 2008-2010: Subinvestigator protocol Studio 01GIMEMA EudraCT: 2006-006210- 14: "Studio prospettico, randomizzato, multicentrico, controllato, sulla terapia antibiotica empirica della febbre nel paziente oncoematologico neutropenico: piperacillina/tazobactam + tigeciclina Vs. una monoterapia con piperacillina/tazobactam."
- 2007-2010: management of *Italian Thrombocythemia Registry* (RIT) for "Centro malattie rare del Sangue e degli Organi emopoietici", Hematology Department "S. Santo" Hospital, Pescara
- 2017: Principal Investigator for study GIMEMA ESTIT ITP 0815: Eltrombopag as Second line Therapy in adult patients with primary Immune Thrombocytopenia (ESTIT study) in an attempt to achieve long-term remission: a single arm multicenter phase II clinical and biological study. Eudract 2015-001327-23, CE 62/16
- 2017: Principal Investigator for study Low- Pw randomized trial, benefit/risk profile of Pegylated proline-Interferon alpha-2b (AOP2014) added to the best available strategy based on phlebotomies in low-risk patients with Polycythemia Vera (PV). Eudract 2015-004717-25, CE 84/16
- 2018: Principal investigator in Randomized phase III study of decitabine with or without HU in CMML. Eudract 2014-000200-10, CE 101/15
- 2018: Principal Investigator for study Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes. (EQoI-MDS). Eudract 2010-022890-33, CE 85/18
- 2018: Principal Investigator for study MPN-K: Secondary Cancers in Myeloproliferative Neoplasms, CE 34/18
- 2018: Principal investigator in A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia. Eudract 2017-003652-22, CE 149/18
- 2018: Principal Investigator for study MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), alone or in Combination with Ruxolitinib Primary Myelofibrosis. Eudract 2018-000579-34, CE 17/19
- 2019: Principal Investigator in A phase II, single-arm, multicenter study of full treatmentfree remission in patients with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have achieved a sustained deep molecular response for at least 1 year: DANTE study. Eudract 2018-002898-21, CE 20/19
- 2019: Principal Investigator in Phase 3, randomized study ob Guadecitabine (SGI-110) versus physician's choice in adults with MDS or CMML previously treated with hypomethylating agents. Eudract 2015-005257-12, CE 75/18
- 2019: Principal Investigator for study GIMEMA ITP0918, Italian registry of ITP. Clinicaltrial number NCT03465020, CE 88/19
- 2020: Principal Investigator for study 74494550MDS2001, A Phase 2, Randomized, Open-label Study of Cusatuzumab in Combination with Azacitidine Compared with Azacitidine Alone in Patients with Higher-risk

Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and who are not candidates for Hematopoietic Stem Cell Transplantation (HSCT) . Eudract 2019-003576-40, CE 174/20

15. 2020: Principal Investigator for study SRA-MMB-301, SA Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy. Eudract 2019-000583-18, CE 107/20

16. 2020-: Principal Investigator for study MOM-M281-006, Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study. Eudract 2019-000720-17, CE 173/19

17. 2020-: Principal Investigator for study FORWARD, a randomized study of Phase 3 multi-center,, double-blind, placebo-controlled, parallel group study to investigate the efficacy of 24 weeks of treatment with fostamatinib (R788) vs. placebo in achieving a hemoglobin response in subjects with wAIHA. Eudract 2018-004774-97, CE 10/20

18. 2020: Principal Investigator for study EMPATHY, Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients with Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to Therapy: The EMPATHY Pilot Study, CE 173/20

19. 2020: Principal Investigator for study ARGX-113-1801 (ADVANCE), A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous Thrombocytopenia. Eudract 2019-002100-41, CE 77/20

20. 2020: Principal Investigator for study ARGX-113-1803 (ADVANCE+), A Phase 3, Multicenter, open label Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous Thrombocytopenia. Eudract 2019-002101-21, CE 172/20

PUBLICATIONS

1. **Patriarca A**, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A. Is JAK2V617F mutation absence a risk factor for bleeding in Essential Thrombocythemia? An analysis on 106 patients. *Blood Transfusion* 2010; 8: 21-7.
2. Lorella Mellillo, Alessia Tieghi, Anna Candoni, Franca Radaelli, Rosanna Ciancia, Giorgina Specchia, Bruno Martino, Potito Rosario Scalzulli, Roberto Latagliata, Fausto Palmieri, Emilio Usala, Daniela Valente, Maria Rosa Valvano, Michele Cedrone, Giuseppina Comitini, Vincenzo Martinelli, Nicola Cascavilla, and Luigi Gugliotta. Outcome of 122 pregnancies in essential thrombocythemia patients: A report from the Italian registry. *American Journal of Hematology* 2009 Oct;84(10):636-40.
3. Salutari P, **Patriarca A**, D'Arcangelo L and Fioritoni G. Chylous ascites. *BloodMed.com* 2009 Case report and images.
4. **Patriarca A**, Colaizzo D, Tiscia G, Spadano R, Di Zacomo S, Spadano A, Villanova I, Margaglione M, Grandone E, Dragani A. TET2 mutations in Ph- negative-Myeloproliferative Neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings. *Biomed Res Int.* 2013;2013:929840. doi: 10.1155/2013/929840.
5. **Patriarca A**, Salutari P, Pulini S. Images 374: plasma cell leukaemia recurring with serous effusion. *BloodMed.com* 2014
6. **Patriarca A**, Salutari S, Di Zacomo S. The impact of molecular genetic in Acute Myeloid Leukemias. *J Blood Disorders Transf* 6:252. doi: 10.4172/2155-9864.1000252
7. Giordano G, Mondello P, Tambaro R, Perrotta N, D'Amico F, D'Aveta A, Berardi G, Carabellese B, **Patriarca A**, Corbi MG, Di Marzio L, Licianci A, Berardi D, Di Lullo L and Di Marco R. Biosimilar epoetin alpha is as effective as originator epoetin-alpha plus liposomal iron (Sideral), vitamin B12 and folates in patients with refractory anemia: a retrospective real-life approach. *Molecular and Clinical Oncology* 2015; 3: 781-784.
8. **Patriarca A**, Giordano G. Reed Sternberg Cells in Bone Marrow Touch Imprints. *J Blood Disord Transfus* 2015, S4:1 <http://dx.doi.org/10.4172/2155-9864.1000S4-i101>
9. Moia R, Favini C, Rasi S, Deambrogi C, Ferri V, Schipani M, Sagiraju S, Mahmoud AM, Kodipad AA, Adhinaveni R, **Patriarca A**, Nassi L, Gaidano G. Liquid biopsy in lymphomas: a potential tool for refining diagnosis and disease monitoring. *J Cancer Metastasis Treat* 2019;5:67
10. Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, **Patriarca A**, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. *Leukemia*, 2019, volume 33, pages1996–2005.
11. Ecsedi M, Lengline E, Knol-Bout C, Bosman P, Eikema DJ, Afanasyev B, Maschan A, Dreger P, Halkes CJM, Drexler B, Cortelezzi A, Drénou B, **Patriarca A**, Bruno B, Onofrillo D, Lanino E, Pulanic D, Serventi-Seiwerth D, Garnier A, Ljungman P, Bonifazi F, Giammarco S, Tournilhac O, Pioltelli P, Rovó A, Risitano AM, Peffault de Latour R, Dufour C, Passweg J. Use of eltrombopag in aplastic anemia in Europe. *Annals of hematology* 2019, 98 (6), 1341-1350
12. Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscazzini A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, **Patriarca A**, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben F, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M,

- Deaglio S, Foà R, Gaidano G, Rossi D. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. *Haematologica*, haematol. 2019.219550
13. Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, Abruzzese E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M, **Patriarca A**, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi M, Binotto G, Vignetti M, Rosti G. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. *Leukemia*. 2020 Feb;34(2):488-498.
 14. Moia R, **Patriarca A**, Deambrogi C, Rasi S, Favini C, Kodipad AA, Schipani M, Gaidano G. An update on: molecular genetics of high-risk chronic lymphocytic leukemia. *Expert Rev Hematol*. 2020 Feb;13(2):109-116.
 15. De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, **Patriarca A**, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. *Blood*. 2020 Jan 30;135(5):381-386.
 16. Moia R, Boggio E, Gigliotti L, Crisà E, De Paoli L, Margiotta Casaluci G, Rolla R, **Patriarca A**, Gaidano G, Dianzani U, Bruna R. Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity. *Hematol Oncol*. 2020 Apr;38(2):204-206.
 17. Caocci G, Vignetti M, **Patriarca A**, Breccia M, Platzbecker U, Palumbo GA, Stauder R, Cottone F, Petranovic D, Voso MT, Tafuri A, Invernizzi R, Caers J, Luppi M, La Nasa G, Niscola P, Efficace F. High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. *Int J Hematol*. 2020 Aug;112(2):141-146.
 18. Bruno Fattizzo, Marc Michel, Anna Zaninoni, Juri Giannotta, Stephanie Guillet, Henrik Frederiksen, Jose Fattizzo B, Michel M, Zaninoni A, Giannotta J, Guillet S, Frederiksen H, Vos JMI, Mauro FR, Jilma B, **Patriarca A**, Zaja F, Hill A, Berentsen S, Barcellini W. Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study. *Haematologica*. 2020 Apr 30;haematol.2020.250522. doi: 10.3324/haematol.2020.250522.
 19. Efficace F, Cottone F, Oswald LB, Cella D, **Patriarca A**, Niscola P, Breccia M, Platzbecker U, Palumbo GA, Caocci G, Stauder R, Ricco A, Petranovic D, Caers J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P, Vignetti M. The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. *Leukemia*. 2020 Sep;34(9):2451-2459.
 20. Pinato DJ, Lee AJX, Biello F, Seguí E, Aguilar-Company J, Carbó A, Bruna R, Bower M, Rizzo G, Benaffif S, Carmona C, Chopra N, Cruz CA, D'Avanzo F, Evans JS, Galazi M, Garcia-Fructuoso I, Dalla Pria A, Newsom-Davis T, Ottaviani D, **Patriarca A**, Reyes R, Sharkey R, Sng CCT, Wong YNS, Ferrante D, Scotti L, Avanzi GC, Bellan M, Castello LM, Marco-Hernández J, Mollà M, Pirisi M, Ruiz-Camps I, Sainaghi PP, Gaidano G, Brunet J, Tabernero J, Prat A, Gennari A. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. *Cancers (Basel)*. 2020 Jul 8;12(7):1841.
 21. **Patriarca A**, Gaidano G. A step ahead toward precision medicine for chronic lymphocytic leukemia. *Haematologica*. 2020 Jun 5;105(10):2352-2355.
 22. Moia R, Greco M, Boggione P, Nicolosi M, Bruna R, **Patriarca A**, Gaidano G, Lunghi M. Cerebrospinal fluid xanthochromia after pegasparginase hepatotoxicity in B-cell acute lymphoblastic leukemia. *Clin Case Rep*. 2020 Jul 16;8(11):2293-2294.
 23. Efficace F, Iurlo A, Patriarca A, Stagno F, Bee PC, Ector G, Capodanno I, Elena C, Bonifacio M, Blijlevens NMA, Caocci G, Wan C, Abruzzese E, Breccia M, Cottone F, Okumura I, Oerlemans S, Cascavilla N, Albano F, Kota V, Sztankay M, Miggiano MC, Saussele S, Di Renzo N, Sorà F, Castagnetti F, Baccarani M, Vignetti M, Rosti G. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. *Leuk Lymphoma*. 2020 Nov 6:1-10.
 24. Lunghi M, **Patriarca A**, Greco M, Taherinasab A, Della Starza I, Cavalli M, Gaidano G, Foà R, Chiaretti S. Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia. *Leuk Lymphoma*. 2020 Nov 5:1-3. doi: 10.1080/10428194.2020.1842401. Epub ahead of print. PMID: 33150814.
 25. Moia R, Boggione P, Mahmoud AM, Kodipad AA, Adhinaveni R, Sagiraju S, **Patriarca A**, Gaidano G. Targeting p53 in chronic lymphocytic leukemia. *Expert Opin Ther Targets*. 2020 Oct 19:1-12. doi: 10.1080/14728222.2020.1832465. Epub ahead of print. PMID: 33016796.
 26. Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, Davis ZA, Yan XJ, Jeromin S, Schneider C, Pedersen LB, Tschumper R, Sutton LA, Baliakas P, Scarfò L, van Gastel EJ, Armand M, Tausch E, Biderman B, Baer C, Bagnara D, Navarro A, de Septenville A, Guido V, Mitterbauer-Hohendanner G, Dimovski A, Brieghel C, Lawless S, Meggendorfer M, Stranska K, Ritgen M, Facco M, Tresoldi C, Visentin A, **Patriarca A**, Catherwood M, Bonello L, Sudarikov A, Vanura K, Roumelioti M, Skuhrova Francova H, Moysiadis T, Veronese SM, Giannopoulos K, Mansouri L, Karan-Djurasevic T, Sandaltzopoulos R, Bödör C, Fais F, Kater AP, Panovska-Stavridis I, Rossi D, Alshemmari S, Panagiotidis P, Costeas PA, Espinet B, Antic D, Feroni L, Montillo M, Trentin L, Stavroyianni N, Gaidano G, Francia di Celle P, Niemann CU, Campo E, Anagnostopoulos A, Pott C, Fischer K, Hallek M, Oscier DG, Stilgenbauer S, Haferlach C, Jelinek DF, Chiorazzi N, Pospisilova S, Lefranc MP, Kossida S, Langerak AW, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. *Blood*. 2020 Sep 29;blood.2020007039. doi: 10.1182/blood.2020007039. Epub ahead of print. PMID: 32992344.
 27. Crisà E, Nicolosi M, Ferri V, Favini C, Gaidano G, **Patriarca A**. Atypical Chronic Myeloid Leukemia: Where Are We Now? *Int J Mol Sci*. 2020 Sep 18;21(18):6862. doi: 10.3390/ijms21186862. PMID: 32962122; PMCID: PMC7555965.
 28. Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Mesia R, Segui E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, Maconi A, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D,

Carbo A, Bruna R, Benafif S, Marrari A, Wuerstlein R, Carmona-Garcia MC, Chopra N, Tondini C, Mirallas O, Tovazzi V, Betti M, Provenzano S, Fotia V, Cruz CA, Dalla Pria A, D'Avanzo F, Evans JS, Saoudi-Gonzalez N, Felip E, Galazi M, Garcia-Fructuoso I, Lee AJX, Newsom-Davis T, **Patriarca A**, Garcia-Illescas D, Reyes R, Dileo P, Sharkey R, Wong YNS, Ferrante D, Marco-Hernandez J, Sureda A, Maluquer C, Ruiz-Camps I, Gaidano G, Rimassa L, Chiudinelli L, Izuzquiza M, Cabrita A, Franchi M, Santoro A, Prat A, Taberero J, Gennari A. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. *Cancer Discov.* 2020 Jul 31;10(10):1465–74.

ABSTRACTS:

1. Dragani A, Malizia R, Iuliani O, Di Marzio I, **Patriarca A**, Clissa C, Villanova I, Pompetti F, Di Nicola M, Esposito A, Davi G. The relationship between clinical events and Jak2V617F mutational status in a cohort of 75 patients with Essential Thrombocythemia. *Haematologica* 2007; SIE 2007 Abstract Book
2. Dragani A, Di Marzio I, Malizia R, Iuliani O, Clissa C, **Patriarca A**, Rolandi G, Castaman G, Davi G. The Efficacy Of Recombinant Factor VIIa (Novoseven) In A Patient With Severe Factor XI Deficiency And Abnormal Bleeding. *Haematologica* 2007; SIE 2007 Abstract Book.
3. Di Marzio A, La Barba G, Sau A, **Patriarca A**, Pulini S, Chiarelli F, Mohn A, Di Marzio D, Fioritoni G. Late effects of treatment for Hodgkin Lymphoma: a single center experience. EHA 2008 abstract book.5. Sau A, La Barba G, Pulini S, **Patriarca A**, Recchia A, D'Arcangelo L, Spadano A, Fioritoni G. Platelet gel for Healing sinus pilonidalis in patient with acute lymphoblastic leukemia in chemotherapy. EHA 2008 abstract book.
4. **Patriarca A**, Di Marzio I, D'Aloisio M, Pascale S, Iuliani O, Dragani A. Is the WBC count at diagnosis a risk factor for thrombosis in MPNs? A retrospective single center study on 203 patients. Abstract Book and Poster presentation SIE 2009, Milan.
5. Gugliotta L, Papayannidis C, Piccin A, Tieghi A, Vianelli N, Scalzulli PR, Candoni A, Dragani A, **Patriarca A**, Lunghi M, Ciancia R, Martinelli V, Liberati AM, Specchia G, Imovilli A, Vannucchi AM, Maschio N, Iurlo A, Randi ML, Passamonti F, Palmieri F, Mazzucconi MG, La Tagliata R, Mastrullo L, Cimino G, Pierri I, Cacciola E, Lucchesi A, Luraschi A, Cozzani E, Parodi A, Martinelli G and Baccarani M. Hydroxyurea Treatment In 1075 Patients with Essential Thrombocythemia and Occurrence of Extra- Hematological Adverse Events: A Preliminary Report of the Registro Italiano Trombocitemia (RIT). *Blood*, Volume 116, Issue 21.
6. Gugliotta L, Tieghi A, Codeluppi K, Iurlo A, De Philippis C, Candoni A, Specchia G, Scalzulli P, Dragani A, **Patriarca A**, Ciancia R, Martinelli V, Randi M, Maschio N, D'Arco A, Rago A, Mazzucconi M., Passamonti F., Vannucchi A., Vianelli N. VALIDATED AND CANDIDATE Thrombotic risk factors in Essential Thrombocythemia: preliminary analysis of the Registro Italiano Trombocitemia (RIT). *Haematologica* 2011, 96 (S2); 383.
7. Gugliotta L, Tieghi A, Iurlo A, Candoni A, Specchia G, Lunghi M, Rumi E, Scalzulli PR, Dragani A, Martinelli V, Randi ML, Maschio N, Liberati AM, Palmieri F, Santoro C, D'Arco AM, Rago A, , Chiozzotto C, Mastrullo L, Cacciola E, Cacciola R, Lanza F, Codeluppi K, De Philippis C, **Patriarca A** et al. Thrombosis History and Relationship with Low Thrombocytosis, Leukocytosis, and Jak2 V617F Mutation In A Cohort of 977 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia (RIT). *ASH abstract book* 2011.
8. D'Arena G, Perbellini O, Coscia M, Vitale C, **Patriarca A**, Pizza V, La Rocca F, Ruggieri V, De Feo V, D'Arena G Sr, Pietrantuono G, Visco C, Musto P, Iorio EL. Oxidative stress in Chronic Lymphatic leukemia. *Haematologica* Volume 101, JUNE 2016, s1
9. Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, **Patriarca A**, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Mangiacavalli S, Palumbo A, Corso A. Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study. *Blood* (2016) 128 (22): 4494.
10. D'Auria F, La Rocca F, Simeon V, Statuto T, Pietrantuono G, D'Arena G, Villani O, Mansueto G, **Patriarca A**, Bitetti C, Seneca E, Traficante A, Musto P. Role of heavy/light chain ratio in myeloma patients achieving complete response after first line therapy. *Haematologica*. HAEMATOLOGICA 2017, 102, 516-17.
11. Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, **Patriarca A**, Rumi E, Stephenson C, Guglielmelli P, Elli EM, Miroslava P, Bertolotti L, Erez D, Gomez M, Wille K, Pérez-Encinas M, Lunghi F, Figueras AA, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola RR, McMullin MF, Tieghi A, Flores VL, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G. Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms. *Blood* 2018, *Blood* 132 (Suppl 1), 4279-4279
12. Lucchini E, Palandri F, Volpetti S, Vianelli N, Auteri G, Rossi E, **Patriarca A**, Carli G, Barcellini W, Tosi P, Consoli U, Valeri F, Santoro C, Paoloni F, Fazi P, Boggio E, Dianzani U, Giardini I, Carpenedo M, Fanin R, Zaja F. Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study). *Blood* 2018, 132 (Suppl 1), 1135-1135
13. Efficace F, Niscola P, **Patriarca A**, Cottone F, Palumbo GA, Caocci G, Fedele M, Platzbecker U, Stauder R, Petranovic D, Ricco A, Breccia M, Frairia C, Luppi M, Invernizzi R, Sanpaolo G, Crugnola M, Fianchi L, Vallisa D, Voso MT, Fozza C, Santini V, Caers J, Capodanno I, Sarlo C, Pelaez Doro M, Bergamaschi M, Zhang H, Lubbert M, Canicatti M, Kyriakou C, Di Renzo N, Cuneo A, Karakantza M, Vignetti M. Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. *Blood* 2018, 132 (Suppl 1), 2293-2293
14. Efficace F, Niscola P, **Patriarca A**, Cottone F, Palumbo GA, Breccia M, Caocci G, Platzbecker U, Specchia G, Stauder R, Fianchi L, Sanpaolo G, Petranovic D, Frairia C, Caers J, Santini V, Bergamaschi M, Capodanno I, Di Renzo N, Vignetti M. Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS)

across all disease risk categories: Analysis of 914 patients. *Journal of Clinical Oncology* 2019, 37 (15_suppl), e18220-e18220

15. Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, **Patriarca A**, Rumi E, Stephenson C, Guglielmelli P, Elli EM, Miroslava P, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G. Impact of cytoreductive drugs on second cancer in myeloproliferative neoplasms: PS1468. *HemaSphere*, 2019, 3, 667-668
16. Fattizzo B, Languille L, Levati G, Mauro FR, Jilma B, **Patriarca A**, Hill A, Berentsen S, Michel M, Barcellini W. Evidence based use of erythropoietin in patients with autoimmune hemolytic anemia: A multicenter international study: S900. *HemaSphere* 2019, 3, 405-406
17. Lucchini E, Palandri F, Volpetti S, Vianelli N, Auteri G, Rossi E, **Patriarca A**, Carli G, Barcellini W, Rotondo F, Consoli U, Valeri F, Santoro C, Crea E, Vignetti M, Boggio E, Dianzani U, Giardini I, Carpenedo M, Rodeghiero F, Fanin R, Zaja F. Eltrombopag as second line therapy in adult patients with primary immune thrombocytopenia (ITP) in attempt to treatment free remission. Updated results of a phase II prospective study by GIMEMA group: PF695. *HemaSphere*, 2019, 3, 302
18. Fattizzo B, Levati G, Languille L, Mauro FR, Jilma B, **Patriarca A**, Hill A, Berentsen S, Michel M, Barcellini W. Evidence based use of erythropoietin in patients with autoimmune hemolytic anemia: a multicenter international study. *Haematologica* 2019, 104, 26-27
19. Lucchini E, Palandri F, Volpetti S, Vianelli N, Auteri G, Rossi E, **Patriarca A**, Carli G, Barcellini W, Rotondo F, Consoli U, Valeri F, Santoro C, Crea E, Vignetti M, Boggio E, Dianzani U, Giardini I, Carpenedo M, Rodeghiero F, Fanin R, Zaja F. Eltrombopag as second line therapy in adult patients with primary immune thrombocytopenia (ITP) in attempt to treatment free remission. Updated results of a phase II prospective study by GIMEMA group (the ESTIT study). *Haematologica* 2019, 104, 32-32
20. Harrison CN, **Patriarca A**, Mascarenhas J, Kremyanskaya M, Hoffman R, Schiller GJ, Leber B, Devos T, Kabir S, Senderowicz A, Mertz J, Trojer P, Shao J, Gupta V. Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients. *Blood* 2019, 134, 4164
21. De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, **Patriarca A**, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille L, Pérez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola RR, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larrán A, Vannucchi AM, Rambaldi A, Barbui T. Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. *Blood* 2019, 134, 4170
22. Fattizzo B, Michel M, Languille L, Giannotta J, Frederiksen H, Mauro FR, Jilma B, Lucchini E, **Patriarca A**, Zaja F, Hill A, Berentsen S, Barcellini W. Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia. *Blood* 2019, 134, 3516.

Books and chapters:

1. **Patriarca A**, Gaidano G. 28. Leucemia linfatica cronica, Hairy Cell Leukemia, Leucemia prolinfocitica, LGL Leukemia, in *Ematologia per Medicina – Scienze Biologiche – Biotecnologie Mediche*, a cura di Nicola Giuliani ed Attilio Olivieri. Idelson Gnocchi 2020; ISBN: 9788879477093.
2. Bjoerg Kristensen H, **Patriarca A**, Delaisse J-M. Visualizing Normal and Malignant Human Stem and Progenitor Cells in Histological Sections, In *Encyclopedia of Bone Biology* 2020, Pages 50-61. Elsevier. DOI: 10.1016/B978-0-12-801238-3.11159-6.

Novara, 09/12/2020


